We use cookies for behaviour analytics. Learn more
Healthcare · Equity Analysis
Novo Nordisk A/S (NVO) Stock Analysis - DCF Valuation & AI Disruption Risk
By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
NVO — ADR ~$48 (down 56% from ATH): Medicare patient preference study shows 2:1 pill-over-injection preference (June 24); Wegovy pill surpassed 3M prescriptions; zenagamtide (amycretin) Phase 2 positive at ADA 2026 (up to 14.6% weight loss, A1C reduction), Phase 3 launch H2 2026. Medicare bridge program July 1. Oral semaglutide 25mg FDA Q4 2026 is make-or-break catalyst vs LLY's Foundayo head-to-head win.
Composite rating with analyst overlay — not individualized investment advice.
How Is This Rating Calculated?
A.L. Capital Advisory Equity Composite model · calculated 2026-08-08. Four calculation steps, in order — steps 1, 2 and 4 are rules-based; step 3 is a disclosed qualitative analyst overlay mapped to a fixed numerical scale:
1. Margin of safety → quantitative grade
NVO's margin of safety is +26.72% (base case $64 vs. price $47.26). Margin of safety here is defined as (fair value − price) / fair value — this is the formula the quant grade below is actually assigned from. It is not the same figure as the gauge's "Upside to Base" pill above, which uses (fair value − price) / price and will read a larger number for the same inputs. For comparison, the pure (unblended) DCF output alone implies a margin of safety of +50.96% (pure DCF base $96 vs. price $47.26) — the gap between this and the +26.72% blended figure above reflects the analyst-consensus blend.
Rules are cumulative (multiple can fire on the same ticker) and purely mechanical — no analyst judgment is involved in step 2.
3. Thesis conviction modifier
Analyst conviction: high · modifier: +0.60. This is a qualitative analyst judgment on the written thesis, mapped to a fixed numeric modifier below — it is not algorithmically derived from a measurable indicator.
Analyst-conviction modifier scale
Conviction level
Modifier
Very High
+1.00
High
+0.60
Medium
+0.00
Low
-0.60
Very Low
-1.00
General guidance for the assigning analyst (not an algorithmic rule — conviction is assigned by editorial judgment on the written thesis, not computed): Very High/High — multiple thesis pillars confirmed by the most recent reported quarter, no unresolved red flags. Medium — mixed evidence, or a thesis not yet differentiated enough to lean either direction. Low/Very Low — one or more thesis pillars deteriorating, or a material data-quality concern. Assigned and reviewed each time the underlying thesis is updated (see the thesis "last updated" date on this page).
This is the exact formula the model runs — not a post-hoc explanation. Source: composite_grade.py, A.L. Capital Advisory Equity Composite.
NVO Price Target & Rating
NVO's composite rating is Buy (quantitative grade: Strong Buy), with significant tail risk (CVaR -42.2%), and quality metrics (net margin 35%, ROE 60%). Novo Nordisk A/S (NVO) trades at $47.26 with a Buy composite rating and a quantitative grade of Strong Buy: a trailing P/E of 11.4x at a 48% discount to sector median, net margins of 35.3%, a blended fair-value range of $50–$89 suggesting a +27% margin of safety, beta 0.35 (defensive risk profile).
What Is NVO's DCF Intrinsic Value and Blended Fair Value Range?
NVO's blended fair-value range is $50–$89 (base case $64), against a current price of $47.26.
NVO blended fair-value gauge — bear case $50, base case $64, bull case $89, current price $47.26.
Price & DCF data as of
How Does NVO's Margin of Safety Change as the Price Moves?
Drag to simulate NVO's price moving between the blended bear ($50) and bull ($89) fair-value anchors — left for a price fall, right for a rise — and see how the margin of safety vs A.L. Capital Advisory's $64 blended base-case fair value changes. Starting point: the page's as-of price of $47.26 on 2026-08-08.
DCF Assumptions
Two-stage earnings-based DCF on forward EPS of $3.34 (Yahoo Finance forwardEps: provider-aggregated next-fiscal-year consensus estimate, not a fixed trailing-12-month window): explicit 5-year forecast at the stage-1 growth rate below, discounted at the CAPM cost of equity, plus a Gordon Growth terminal value at the terminal growth rate, also discounted at the CAPM cost of equity. This model discounts projected EPS — an equity-level metric — directly, not free cash flow, so the cost of equity is the theoretically correct discount rate; this is not a debt-weighted WACC (no cost of debt or capital-structure weighting is applied). Source: A.L. Capital Advisory DCF engine (api.py).
DCF assumptions by scenario
Input
Bear
Base
Bull
Stage-1 (near-term) growth
4.50%
10.00%
15.00%
Terminal growth
2.50%
2.50%
2.50%
CAPM cost of equity (discount rate)
8.00%
7.41%
6.82%
Forecast horizon
5 years
5 years
5 years
CAPM cost of equity = risk-free rate (4.66%, a live 10-year Treasury yield (Yahoo Finance ^TNX) fetched at page-generation time, 2026-08-08T10:25:55+00:00 UTC) + beta (0.50) × 5.5% equity risk premium, floored at 6% and capped at 18%. Stage-1 growth is a sector-level base rate (bear/bull apply 0.45x/1.50x multipliers); terminal growth is held constant across scenarios. Bear/bull cost of equity applies a ±8% relative adjustment to the base rate, clamped to the same 6–18% band.
The DCF output above is not the final intrinsic value shown elsewhere on this page. It is blended with the Wall Street analyst consensus price target to avoid extreme single-model divergence, weighted by analyst coverage depth (12 analysts covering this stock → 35.00% DCF / 65.00% consensus). The blended figure is the intrinsic value used for margin-of-safety and the composite rating.
DCF-to-intrinsic-value blend by scenario
Scenario
Pure DCF value
Analyst target used
Blended intrinsic value (displayed)
Bear
$67.82
$40.41
$50.00
Base
$96.38
$47.32
$64.49
Bull
$135.49
$63.79
$88.88
Blended value = (35.00% × pure DCF) + (65.00% × analyst target). Bear/bull scenarios blend against the analyst low/high target rather than the mean.
Analyst-coverage-to-consensus-weight tiers
Analyst coverage
Weight
0–1 analysts
0.00% consensus / 100.00% DCF
2–4 analysts
40.00% consensus / 60.00% DCF
5–19 analysts
65.00% consensus / 35.00% DCF
20+ analysts
75.00% consensus / 25.00% DCF
The consensus weight is a fixed step function of analyst coverage depth (above), not adjusted for target age, dispersion, or outliers — the mean/low/high analyst targets are used as reported by the data provider with no filtering.
Risk: CVaR -42.2% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.35 amplifies broad market moves in both directions
Strengths: Quality 5.0/5, Size 4.5/5, 35% net margin, 60% ROE dominate the factor profile
Catalyst: Medicare GLP-1 bridge program July 1 (oral semaglutide volume ramp); Oral semaglutide 25mg FDA decision Q4 2026 — critical make-or-break; Zenagamtide Phase 3 initiation H2 2026; CagriSema higher-dose trial data; Q3 2026 earnings — US GLP-1 market share vs LLY Foundayo
Bear catalyst: Foundayo captures >40% oral GLP-1 U.S. market share by Q1 2027; amycretin Phase 2 signal disappoints; semaglutide U.S. price negotiated below $250/month list equivalent
NVO — Quantitative SnapshotAugust 2026
RatingBuy
Price$47.26
Why BuyHigh-quality business at a reasonable valuation with constructive earnings momentum
Main riskElevated tail risk — CVaR -42.2% on a one-month horizon
Tail riskCVaR -42.2% over one month at the 95th percentile
Blended fair-value range$50–$89 blended fair-value range; margin of safety +27%
Best useCore large-cap Healthcare holding — not a source of diversified sector exposure
Next watchEarnings delivery consistency and margin trajectory
How Does NVO Score on the Five-Factor Quantitative Model?
NVO's composite five-factor score is 4.4/5, led by Quality (5.0/5) and weakest on Momentum (3.0/5).
NVO five-factor radar — Value 4.5, Quality 5.0, Momentum 3.0, Volatility 5.0, Size 4.5 (out of 5).
Value
4.5 / 5
Quality
5.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.5 / 5
NVO Five-Factor Quantitative Scores
Factor
Score
Value
4.5 / 5
Quality
5.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.5 / 5
What Is NVO's AI-Era Durability and Disruption Risk?
AI Disruption Risk: Elevated
Novo Nordisk's durability risk is competitive, not AI-driven: the company still leads on oral GLP-1 launch volume -- oral Wegovy logged roughly 146,000 weekly scripts versus Lilly's Foundayo at ~20,000 -- but it is losing the broader obesity-market battle to Lilly's tirzepatide, which delivers a meaningfully larger average weight loss (~20% vs ~14%) and already commands the larger share of new U.S. injectable prescriptions. Novo has responded by cutting list prices roughly in half (oral Wegovy now $149/month self-pay) to defend volume, a move that compresses margins even as it slows share loss. There is no disclosed AI initiative of comparable scale to Lilly's NVIDIA/Insilico deals or manufacturing-AI story; Novo's 2026 narrative is almost entirely about defending obesity-market position through pricing and its oral-pill head start rather than technology differentiation. The watch trigger is relative prescription share trends between oral Wegovy and Foundayo through 2H26, plus whether Novo's price cuts stabilize U.S. volume.
Key Metrics
NVO Key Metrics — Novo Nordisk A/S 2026
Metric
Value
Current Price
$47.26
P/E Ratio (TTM)
11.4x
Forward P/E
14.2x
P/S Ratio
0.6
EV/EBITDA
1.8
Beta
0.35
Net Margin
35.3%
ROE
59.8%
Debt/Equity
63.3%
Dividend Yield
3.92%
CVaR (95%, 1M)
-42.2%
Market Cap
$208.9B
1-Month CVaR Methodology
The 1M CVaR-95 figure shown in Key Metrics, the peer comparison table and this page's hero card is computed as follows:
Lookback: most recent 1 year of daily prices.
Return input: daily log returns on dividend/split-adjusted close prices.
Confidence level: 95% (worst 5% of the resulting rolling-month observations).
Quantile convention: floor-based cutoff — the worst floor(N × 0.05) rolling-month observations (minimum 1), not a rounded or interpolated percentile.
CVaR: arithmetic mean of that worst-5% tail, expressed as a percentage.
Corporate actions: reflected via adjusted-close pricing (dividends and splits are accounted for).
1M CVaR-95 by lookback window
Method
1M CVaR-95
Trailing 1-year historical
-42.2%
Trailing 3-year historical
-34.5%
Trailing 5-year historical
-30.6%
The 1-year figure is what appears elsewhere on this page. Because it is built from overlapping 21-day windows over a single year, it reflects roughly the last ~11 non-independent tail events and is sensitive to the specific market regime of that year — treat it as a trailing-window historical estimate, not a structurally stable long-run risk parameter. The 3- and 5-year figures use the same methodology over longer, more regime-diverse histories.
This is a separate calculation from the 1-Day VaR/CVaR shown in the Tail Risk Profile chart below, which uses raw (non-overlapping) daily returns rather than rolling monthly sums — see that chart's own methodology note for the daily-horizon convention.
Tail Risk Profile
Historical Simulation · Daily Log Returns
NVO — Daily Return Distribution
Novo Nordisk A/S · 250 trading days · CVaR illustrated on real data
Aug 2025 – Aug 2026
Daily log returns
95%
-3.11%
1-Day VaR · 95%
95th-percentile loss threshold
-7.22%
1-Day CVaR · 95%
Avg loss in tail
13
Days in tail
of 250 sessions
250
Daily returns
Aug 2025 – Aug 2026
Historical VaR uses the nearest-rank convention: the worst observation within the tail (empirical (1−confidence) fraction of trading days). Historical CVaR is the arithmetic mean of all observations at or below that VaR threshold — so VaR is always included inside the CVaR tail, not one observation outside it.
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-08-08
Rating Rationale
NVO — ADR ~$48 (down 56% from ATH): Medicare patient preference study shows 2:1 pill-over-injection preference (June 24); Wegovy pill surpassed 3M prescriptions; zenagamtide (amycretin) Phase 2 positive at ADA 2026 (up to 14.6% weight loss, A1C reduction), Phase 3 launch H2 2026. Medicare bridge program July 1. Oral semaglutide 25mg FDA Q4 2026 is make-or-break catalyst vs LLY's Foundayo head-to-head win.
Investment Thesis
↑ Bull Case
Oral semaglutide 25mg (oral Wegovy): EMA positive opinion, EU launch H2 2026, U.S. decision Q4 2026; early Rx data showing ~18,400 Rxs/week — vs Foundayo's ~3,700 in comparable period — dominant oral GLP-1 prescription lead
At 13.5x forward P/E vs 5-year historical average 27.9x — implies exceptional mean reversion potential; trading at 19% discount to pharma sector median
Wegovy U.S. market share: 65% of new GLP-1 Rxs despite CagriSema disappointment — injectable franchise remains structurally dominant
Amycretin (zenagamtide, oral GLP-1/amylin co-agonist): Phase 2b results (ADA June 2026) showed 14.6% body weight reduction and -1.71pp A1C in T2D at 36 weeks — advancing to Phase 3; obesity weight loss expected materially higher than T2D data; potential category-defining drug for 2028+ if Phase 3 obesity data confirms superiority
DKK 55B capex building out manufacturing: long-term GLP-1 production capacity investment signals confidence in market size regardless of near-term competition
Medicare patient preference study (June 24): 2:1 preference for GLP-1 pill over injection among seniors directly validates the oral semaglutide 25mg commercial thesis; with 3M+ Wegovy pill prescriptions already filled and Medicare bridge program July 1, NVO has first-mover injectable-to-oral conversion momentum ahead of FDA Q4 2026 approval
Zenagamtide (amycretin) Phase 2 at ADA 2026: up to 14.6% weight loss + A1C reduction in T2D patients; Phase 3 launch H2 2026 opens next-generation dual-receptor agonist upside and demonstrates NVO's post-CagriSema pipeline depth beyond semaglutide
↓ Bear Case
CagriSema REDEFINE 4 (Feb 2026): failed non-inferiority vs tirzepatide — 23% weight loss but statistically insufficient vs Zepbound; the drug intended to decisively win next-gen obesity war failed
Underlying business contracted ~4% CER in Q1 2026 (adjusted for DKK 26.8B 340B reversal); Ozempic -8% YoY reflects pricing headwinds overwhelming volume
Lilly's Foundayo (oral GLP-1 without food/water restrictions) and retatrutide (triple agonist) represent structural competitive threats to semaglutide-based franchise
Semaglutide LOE in Brazil, Canada, China — generic entry risk in key international markets reduces premium pricing window
GLP-1 price negotiation risk: if MFN or Medicare negotiation sets semaglutide price materially below current, gross margin compression is severe given DKK 55B capex
LLY Foundayo (orforglipron) beat oral semaglutide on A1C AND weight in ACHIEVE-3 head-to-head trial — oral GLP-1 head-to-head loss eliminates NVO's prior first-mover advantage narrative; if oral semaglutide 25mg FDA approval is followed by commercial underperformance vs Foundayo, the entire valuation recovery thesis collapses
What Changes the Rating
↑Catalyst:Amycretin Phase 3 obesity data shows >25% weight loss (Phase 2b T2D was 14.6%); U.S. oral semaglutide captures >60% of oral GLP-1 Rxs within 3 months of launch; CagriSema salvage trial succeeds
↓Model downgrade conditions:Foundayo captures >40% oral GLP-1 U.S. market share by Q1 2027; amycretin Phase 2 signal disappoints; semaglutide U.S. price negotiated below $250/month list equivalent
Anton’s personal note
The model rates this a Buy, and the DCF case is real — the margin of safety is wide enough to absorb some delivery variance. That gives me more conviction here than the factor scores alone would suggest. The DCF gap is striking — the model sees 36% upside, and market consensus is not pricing it. I watch for the catalyst that closes that gap: an earnings beat that resets forward estimates, a sector re-rating, or a margin inflection. Without a visible catalyst, valuation gaps can stay wide longer than logic suggests they should. If the thesis holds across the next two quarters, I would be comfortable carrying this at a meaningful weight. If not — specifically, if margins disappoint or the earnings beat streak breaks — I would reduce before the market fully reprices.
— Anton Ladnyi, CFA
Earnings History
NVO Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est. (consensus)
EPS Actual (adjusted, consensus basis)
Surprise
Q2 2026
$4.98
$6.18
+24.0% ✓
Q1 2026
$6.96
$6.63
-4.8% ✗
Q4 2025
$5.90
$6.04
+2.3% ✓
Q3 2025
$4.24
$4.50
+6.0% ✓
EPS Actual is on the same adjusted/non-GAAP basis as the consensus estimate it is compared against (excludes one-time items, consistent with how Wall Street EPS estimates are typically constructed) — it will generally differ from the company's GAAP diluted EPS as reported in its official financial statements. Verify the GAAP figure against the issuer's original earnings release if that basis is what you need.
How Has NVO Performed vs. Wall Street EPS Estimates?
NVO has beaten consensus EPS estimates in 3 of the last 4 reported quarters (75%).
NVO quarterly EPS — estimate vs. actual, 4 most recent reported quarters, 75% beat rate.
Earnings Projections
NVO Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q3 2026
$4.87
+8.2%
3
Q4 2026
$4.41
-27.0%
3
Q1 2027
~$6.35
-4.2%
8
Q2 2027
~$5.40
-12.6%
8
~ Estimated from annual consensus — not a direct analyst survey
What Are Wall Street's EPS Estimates for NVO?
Wall Street's next-quarter consensus EPS estimate for NVO is $4.87.
NVO consensus EPS estimates, next quarter $4.87, 4 quarters shown.
Revenue growth × exit multiple (editorial, not mechanically reproducible from disclosed inputs) · hover each scenario for detail · current price $47.26
▼
Bear Case
$28
-40.8%
Implied NTM P/E: 1.3x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
-5.0 revenue CAGR · 10.0 exit multiple
◆
Base Case
$62
+31.2%
Implied NTM P/E: 2.9x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
8.0 revenue CAGR · 16.0 exit multiple
▲
Bull Case
$98
+107.4%
Implied NTM P/E: 4.7x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
18.0 revenue CAGR · 22.0 exit multiple
How Correlated Is NVO With Its Sector Peers?
0 of 10 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
NVO pairwise correlation heatmap across 5 peers — 0 of 10 pairs above 0.60.
0 of 10 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is NVO a buy, hold, or sell?
NVO carries a quantitative grade of Strong Buy. At a trailing P/E of 11.4, the stock trades at a 48% discount to the Healthcare sector median of 22.0x. Our two-stage, EPS-based DCF model produces a pure model range of $68–$135. After blending with Street consensus targets, the displayed fair-value range is $50–$89 — implying a +27% margin of safety vs. blended base fair value at the current price of $47.26. The width of the range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
The company has beaten estimates in 75% of the last 4 reported quarters. The most recent quarter delivered a 24.0% earnings surprise. Analyst estimate revisions are trending downward.
What are NVO's key risk factors?
With a beta of 0.35, NVO exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -42.2% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this standalone tail outcome corresponds to approximately 4.2% of portfolio value before accounting for correlations with other holdings — not a marginal portfolio CVaR contribution, which depends on the full covariance structure. Net margins of 35.3% are significantly above the Healthcare sector average of 18%, reflecting durable pricing power. Return on equity of 59.8% indicates highly efficient capital allocation. The balance sheet is conservatively leveraged at 63% debt-to-equity.
At 0.56, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 34.9% is below realized volatility of 47.6%, potentially making options relatively cheap. Short interest is low at 1.0% of float, suggesting limited bearish conviction.
How does NVO fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — NVO carries a beta of 0.35, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, NVO shows the strongest co-movement with PFE (0.25), ABBV (0.24), LLY (0.20). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The NVO analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning NVO’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
Investor FAQ
What is NVO's AI-Era Durability & Disruption Risk Score?
Novo Nordisk's durability risk is competitive, not AI-driven: the company still leads on oral GLP-1 launch volume -- oral Wegovy logged roughly 146,000 weekly scripts versus Lilly's Foundayo at ~20,000 -- but it is losing the broader obesity-market battle to Lilly's tirzepatide, which delivers a meaningfully larger average weight loss (~20% vs ~14%) and already commands the larger share of new U.S. injectable prescriptions. Novo has responded by cutting list prices roughly in half (oral Wegovy now $149/month self-pay) to defend volume, a move that compresses margins even as it slows share loss. There is no disclosed AI initiative of comparable scale to Lilly's NVIDIA/Insilico deals or manufacturing-AI story; Novo's 2026 narrative is almost entirely about defending obesity-market position through pricing and its oral-pill head start rather than technology differentiation. The watch trigger is relative prescription share trends between oral Wegovy and Foundayo through 2H26, plus whether Novo's price cuts stabilize U.S. volume.
What is NVO's intrinsic value and DCF price target?
A.L. Capital Advisory's model produces a blended fair-value range (25% pure DCF, 75% analyst consensus for well-covered names) of $50 (bear case) to $89 (bull case) for Novo Nordisk A/S (NVO). At $47.26, the margin of safety vs. blended base case is +27% (positive = discount to fair value; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and the CAPM cost of equity (this model discounts EPS, an equity-level metric, so the cost of equity rather than a debt-weighted WACC is the applicable discount rate). Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
Is NVO a buy or sell in 2026?
Novo Nordisk A/S (NVO) carries a Buy composite rating from A.L. Capital Advisory, consisting of a Strong Buy quantitative grade plus an analyst-conviction overlay. The quantitative grade is set by margin-of-safety band; the overlay is an additive analyst adjustment disclosed in the page's rating-calculation breakdown. Five-factor model scoring (Value, Quality, Momentum, Volatility, Size) and CVaR tail-risk measurement are shown separately on the page and are not inputs to this specific composite-rating formula. At $47.26, the margin of safety vs. blended base fair value is +27% (blended fair-value range: $50 bear – $89 bull). That places the current price in the Value zone of A.L. Capital Advisory's DCF framework, which sets the quantitative grade component before the analyst-conviction overlay is applied. Composite factor score: 4.4/5. Strongest factor: Quality (5.0/5). Weakest factor: Momentum (3.0/5). Trailing P/E: 11.4x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
What is the average analyst target price for NVO?
Wall Street consensus target for NVO: $47.32 (+0.1% upside from the current price of $47.26). The analyst target range spans $40.41 (most bearish) to $63.79 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory's Buy composite rating is calculated from the blended margin-of-safety grade, applicable automatic fundamental penalties, and a disclosed qualitative analyst-conviction overlay — not from five-factor scores or CVaR, which are supporting diagnostics shown elsewhere on this page. The displayed blended fair value combines the standalone DCF output with Street consensus for well-covered names (see the DCF Assumptions box for the exact blend weight), so it does not track Street consensus mechanically, but it is not fully independent of it either. When the composite rating and the Street consensus recommendation diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Data & Sources (this page) →
How does NVO score on Value, Quality, Momentum, Volatility, and Size?
NVO five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 4.5/5 (strong) — measures the trailing P/E multiple versus the sector median (not the DCF or blended fair-value range, which are separate metrics on this page); Quality 5.0/5 (strong) — captures profitability metrics including return on equity (ROE: 59.8%) and net margin (35.3%) — sustained above-peer ROE and margins are the model's proxy for economic moat and pricing power; Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.5/5 (strong) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 4.4/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory.
What is NVO's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for NVO on a one-month horizon is -42.2%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.35 indicates below-market systematic sensitivity — beta measures historical sensitivity to market moves, not total volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What would trigger a rating upgrade or downgrade for NVO?
Upgrade trigger: Upgrade to Strong Buy on evidence of accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 11.4x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. These triggers are reassessed each time the underlying fundamentals, price, or earnings data refresh — the current Buy rating is not held on a fixed review calendar. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
Does NVO consistently beat earnings estimates?
NVO has beaten consensus EPS estimates in 3 of the 4 most recently reported quarters (75%) — indicating consistent delivery across the latest 4 reported quarters. The most recent reported quarter beat consensus by 24.0%. Sustained above-consensus delivery supports both the Momentum and Quality factor scores and provides a tailwind to the current rating. Across the 4 most recently reported quarters with valid consensus data, a beat rate above 70% signals consistent execution in this model, while a rate below 50% typically corresponds to a Momentum factor score of 3.0/5 or below. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Earnings History (this page) →
How does NVO contribute to portfolio risk and diversification?
NVO carries a beta of 0.35 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: PFE (0.25), ABBV (0.24), LLY (0.20). Holding NVO alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. If a single position such as this one makes up an outsized share of your net worth — employer stock, RSUs, or concentrated equity compensation — a Strategic Session builds the sequencing plan and the written allocation that follows from it. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse NVO?
A.L. Capital Advisory analyses Novo Nordisk A/S (NVO) using a four-part quantitative research framework grounded in CFA Institute standards (not all four parts feed the composite rating formula directly — see below). (1) DCF Valuation: a two-stage earnings-based DCF that projects EPS (not free cash flow) under bear and bull assumptions, discounts at the CAPM cost of equity (the applicable rate for an equity-level metric like EPS, not a debt-weighted WACC) to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude, shown for context alongside the factor scores. The current Buy composite rating for NVO is calculated separately from this broader framework: it consists of a Strong Buy quantitative grade, any automatic fundamental penalty, and a disclosed qualitative analyst-conviction overlay — see this page's Rating Methodology section for the exact formula. Five-factor scoring, CVaR and earnings surprise analysis below are supporting research diagnostics shown separately on this page; they are not direct numerical inputs into this specific composite-rating calculation. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run NVO in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
Retrieved 2026-08-08T10:25:55+00:00 (UTC); see per-quarter analyst counts in Earnings Forecast; individual target ages/dates are not disclosed by the data provider
Most recent exchange settlement date on file with the data provider (exact settlement date not exposed by the provider's API; retrieved 2026-08-08T10:25:55+00:00 UTC)
[6] DCF valuation, five-factor model & composite rating
Calculated 2026-08-08T10:25:55+00:00 (UTC); see Rating Methodology above for the exact formula
Hand-authored thesis commentary (bull/bear case, catalysts, AI-Era Durability Score narrative) is cross-checked against the company's own investor-relations disclosures at time of writing; figures presented as A.L. Capital Advisory estimates are proprietary forecasts, not company guidance, unless explicitly attributed to the issuer.
Market-session status above is derived from the page's UTC generation time using standard NYSE hours (9:30am–4:00pm ET regular session); it does not account for US market holidays and may be inaccurate on those dates.
Download this page's underlying data: JSON → · CSV →
Legal Disclaimer & Important Notices
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-08-08 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Novo Nordisk A/S.
CFA Portfolio Advisory — NVO
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
